ArticleClinical rheumatology2025
Identification of serum exosomal miRNA biomarkers in patients with lupus nephritis.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- miRNAs in Glomerular Diseases: From Pathogenic Insight to Therapeutic Potential: A Narrative Review.Cells · 2026Review
- Exosomal non-coding RNAs in autoimmune diseases: molecular mechanisms and potential applications.Frontiers in immunology · 2026Review
- miR-7974 as a potential biomarker for lupus nephritis and its involvement in disease progression.BMC nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionCharacterized by glomerulonephritis, lupus nephritis (LN) worsens the prognosis of patients with systemic lupus erythematosus (SLE) and contributes to its increased mortality rate. Here, we investigated whether serum exosomal microRNAs (miRNAs) are promising new biomarkers of LN.
methodsSerum exosomes were initially isolated using a reagent-based kit, and total RNA was extracted with the Trizol method. Small RNA sequencing was subsequently performed to identify differentially expressed exosomal miRNAs. Validation of these miRNAs was conducted via real-time quantitative polymerase chain reaction (RT-qPCR) on individual samples from both the training and validation cohorts, leading to the identification of candidate small RNAs specifically associated with LN. Receiver operating characteristic (ROC) curve analysis was employed to evaluate the diagnostic performance of the identified candidates. To further investigate the immune landscape, 12 types of cytokines were quantified using flow cytometry, and their correlations with the candidate miRNAs were analyzed via Spearman rank correlation. Additionally, the biological functions of these miRNAs were explored through enrichment analyses based on Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.
resultsThe levels of hsa-miR-497-5p and hsa-miR-6515-5p were significantly higher in the LN group compared to the SLE without LN group, with a combined area under the ROC curve (AUC) of 0.798. Notably, these two miRNAs demonstrated exceptional discriminative performance in identifying LN patients with mild proteinuria, achieving an AUC of 0.844. Furthermore, flow cytometry analysis revealed markedly elevated serum levels of interferon (IFN)-γ, interleukin (IL)-8, and IL-17 in the LN group compared to healthy controls (HCs). Additionally, IL-6 and IL-17 levels were significantly higher in the LN group compared to the SLE without LN group. Hsa-miR-6515-5p exhibited a strong positive correlation with IL-8 and IFN-γ. Bioinformatic analyses indicated that these exosomal miRNAs may contribute to the progression of LN by regulating key signaling pathways, with the MAPK signaling pathway being prominently implicated.
conclusionsOur study demonstrated that serum exosomal miRNAs, specifically hsa-miR-497-5p and hsa-miR-6515-5p, show significant potential as biomarkers for the early detection and prognosis of LN.
Indexed as
Identifiers
40319190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.